What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations including Semaglutide products sold under the Semalix brand (injection pens in 2mg, 4mg, and 8mg doses, plus oral tablets), some of which are sourced from third-party manufacturers such as Dr. Reddy's Laboratories and MSN Labs. The business operates across India, the US, and Brazil, and the merger of J.B. Chemicals & Pharmaceuticals into the company became effective on 8 July 2026 with an appointed date of 21 January 2026. In Q1 FY27, the India business grew 19% year-on-year, the US business 36%, and Brazil 27%. For FY26, employee expenses were 19.1% of revenue, other operating expenses 24.0%, raw materials 12.6%, and depreciation 8.0%. Capital expenditure ran at 4.8% of FY26 revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from TORRENT PHARMACEUTICALS L's filed financials and exchange disclosures
TORRENT PHARMACEUTICALS L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol TORNTPHARM.
Yes. Over the trailing twelve months TORRENT PHARMACEUTICALS L reported a net profit of ₹2,156 Cr on revenue of ₹15,723 Cr.
Yes. The dividend yield is 0.77% at the current price. It paid out 60% of its profit as dividend in FY26.
No. Debt stands at 0.84× equity, and it carries net debt of ₹13,681 Cr. That is lower than 8% of its 171 Pharmaceuticals peers.
On trailing P/E, TORRENT PHARMACEUTICALS L ranks 147 of 169 in Pharmaceuticals — cheaper than 13% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session TORRENT PHARMACEUTICALS L moves 0.72% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by TORRENT PHARMACEUTICALS L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
